{"id":3923,"date":"2020-11-02T08:01:21","date_gmt":"2020-11-02T07:01:21","guid":{"rendered":"https:\/\/www.ab-science.com\/ab8939-en-oncologie\/"},"modified":"2021-01-21T16:02:38","modified_gmt":"2021-01-21T15:02:38","slug":"ab8939-en-oncologie","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/","title":{"rendered":"AB8939 en oncologie"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]<\/p>\n

AB8939 est un d\u00e9stabilisateur de microtubules synth\u00e9tiques de nouvelle g\u00e9n\u00e9ration<\/strong><\/h3>\n

[\/vc_column_text][vc_single_image image=\u00a0\u00bb1299″ img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column]

<\/span>Facteurs cl\u00e9s de diff\u00e9renciation de la mol\u00e9cule AB8939<\/span><\/div><\/div>
<\/div>[vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline synth\u00e9tis\u00e9, de structure nouvelle, \u00e0 petite mol\u00e9cule chimique, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur les inhibiteurs de la tubuline traditionnels.<\/p>\n

AB8939 a \u00e9t\u00e9 initialement d\u00e9velopp\u00e9 dans la Leuc\u00e9mie My\u00e9lo\u00efde Aigu\u00eb (LMA) car les cellules canc\u00e9reuses prolif\u00e8rent rapidement dans cette maladie. AB8939 est 100 fois plus puissant que la doxorubicine (adriamycine), qui est un m\u00e9dicament de r\u00e9f\u00e9rence dans la LMA. En outre, l’AB8939 n’est pas d\u00e9sactiv\u00e9 par l’enzyme my\u00e9loperoxydase, ce qui constitue un avantage par rapport aux alcalo\u00efdes de la pervenche (vincristine ou vinblastine).<\/p>\n

L’objectif d’AB Science avec le compos\u00e9 AB8939 a \u00e9t\u00e9 de concevoir un m\u00e9dicament ultra-s\u00e9lectif \u00e0 petites mol\u00e9cules, ayant de fortes propri\u00e9t\u00e9s antiprolif\u00e9ratives et un profil de s\u00e9curit\u00e9 acceptable avec une toxicit\u00e9 cardiaque ou neuronale minimale.[\/vc_column_text]

<\/span>Donn\u00e9es pr\u00e9cliniques de la mol\u00e9cule AB8939<\/span><\/div><\/div>
<\/div>[vc_row_inner content_placement=\u00a0\u00bbtop\u00a0\u00bb][vc_column_inner][vc_column_text]Le potentiel th\u00e9rapeutique du AB8939 dans la LMA a \u00e9t\u00e9 d\u00e9montr\u00e9 \u00e0 l’aide de mod\u00e8les de x\u00e9nogreffes d\u00e9riv\u00e9es de patients (PDX) r\u00e9sistants \u00e0 la cytarabine (Ara-C) et \u00e0 l’azacitidine. L’Ara-C est consid\u00e9r\u00e9 comme l’agent cytotoxique le plus pertinent sur le plan clinique pour le traitement de la LMA, tandis que l’azacitidine est un agent d’hypom\u00e9thylation largement utilis\u00e9 pour la LMA1, 2, 3<\/sup>.<\/p>\n

L’AB8939 a consid\u00e9rablement r\u00e9duit la concentration de blast<\/em> dans le sang (38 jours apr\u00e8s la greffe), la moelle osseuse (BM) et la rate (52 jours apr\u00e8s la greffe) par rapport \u00e0 l’azacitidine (Vidaza\u00ae), un agent hypom\u00e9thyl\u00e9ant largement utilis\u00e9 pour la LMA.<\/p>\n

Le potentiel th\u00e9rapeutique de l’AB8939 dans la LMA a \u00e9t\u00e9 d\u00e9montr\u00e9 in vivo \u00e0 l’aide d’un mod\u00e8le PDX r\u00e9sistant \u00e0 l’Ara-C. L’agent unique AB8939 a consid\u00e9rablement r\u00e9duit la concentration de blast<\/em> dans le sang et la moelle osseuse (41 jours apr\u00e8s la greffe) et a diminu\u00e9 la croissance des tumeurs par rapport \u00e0 l’Ara-C.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]R\u00e9f\u00e9rences<\/strong><\/em><\/p>\n

    \n
  1. Humbert M, et al. (2019). Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939. Blood. 134. 2075-2075. 10.1182\/blood-2019-122540.<\/em><\/li>\n
  2. Goubard A, et al. (2019). In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia. Blood. 134. 5142-5142. 10.1182\/blood-2019-127143.<\/em><\/li>\n
  3. Goubard A, et al. (2019). AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes. Blood. 134. 5154-5154. 10.1182\/blood-2019-127021.<\/em><\/li>\n<\/ol>\n

    [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    [vc_row][vc_column][vc_column_text] AB8939 est un d\u00e9stabilisateur de microtubules synth\u00e9tiques de nouvelle g\u00e9n\u00e9ration [\/vc_column_text][vc_single_image image=\u00a0\u00bb1299″ img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline synth\u00e9tis\u00e9, de structure nouvelle, \u00e0 petite mol\u00e9cule chimique, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur les inhibiteurs de la…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3970,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3923","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nAB8939 en oncologie – AB Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB8939 en oncologie\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text] AB8939 est un d\u00e9stabilisateur de microtubules synth\u00e9tiques de nouvelle g\u00e9n\u00e9ration [\/vc_column_text][vc_single_image image=\u00a0\u00bb1299″ img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline synth\u00e9tis\u00e9, de structure nouvelle, \u00e0 petite mol\u00e9cule chimique, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur les inhibiteurs de la…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-21T15:02:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/\",\"name\":\"AB8939 en oncologie – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-11-02T07:01:21+00:00\",\"dateModified\":\"2021-01-21T15:02:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"AB8939 en oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB8939 en oncologie – AB Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/","og_locale":"fr_FR","og_type":"article","og_title":"AB8939 en oncologie","og_description":"[vc_row][vc_column][vc_column_text] AB8939 est un d\u00e9stabilisateur de microtubules synth\u00e9tiques de nouvelle g\u00e9n\u00e9ration [\/vc_column_text][vc_single_image image=\u00a0\u00bb1299″ img_size=\u00a0\u00bbfull\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline synth\u00e9tis\u00e9, de structure nouvelle, \u00e0 petite mol\u00e9cule chimique, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur les inhibiteurs de la…","og_url":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/","og_site_name":"AB Science","article_modified_time":"2021-01-21T15:02:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/","url":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/","name":"AB8939 en oncologie – AB Science","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2020-11-02T07:01:21+00:00","dateModified":"2021-01-21T15:02:38+00:00","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/science\/ab8939-en-oncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/www.ab-science.com\/fr\/science\/"},{"@type":"ListItem","position":3,"name":"AB8939 en oncologie"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=3923"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3923\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3970"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=3923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}